Increased Levels of Modified Advanced Oxidation Protein Products are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients
Restricted accessResearch articleFirst published online July, 2015
Increased Levels of Modified Advanced Oxidation Protein Products are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients
Oxidative stress plays an important role in the pathogenesis of cardiovascular disease (CVD). Central blood pressure (BP) is thought to be more relevant than peripheral BP for the pathogenesis of CVD. Advanced oxidation protein products (AOPP) are markers of oxidative stress. This study investigated the relationship between AOPP and central BP in peritoneal dialysis (PD) patients.
♦Methods
In a cross-sectional study of 75 PD patients (67% men), we analyzed two oxidative stress markers, AOPP (modified assay, mAOPP, correcting for the impact of triglycerides) and pentosidine, three inflammation markers, interleukin-6 (IL-6), tumor necrosis factor (TNF), and high-sensitivity C-reactive protein (hs-CRP). All patients underwent measurement of central systolic blood pressure (SBP) and diastolic blood pressure (DBP) by applanation tonometry.
♦Results
Patients with mAOPP levels above the median had a higher central SBP and DBP than those below the median values. In univariate analysis, the levels of mAOPP associated with central SBP and central DBP. Multiple regression analysis, adjusting for age, gender, diabetes, CVD, protein-energy wasting (PEW), hs-CRP and extracellular water by multi-frequency bioimpedance or N-terminal prohormone of brain natriuretic peptide (NT-proBNP), confirmed independent associations between mAOPP and central SBP and central DBP respectively.
♦Conclusions
The mAOPP level is independently associated with the central SBP and DBP in PD patients. This finding suggests that oxidative stress may be involved in the pathogenesis of hypertension or that hypertension itself or factors associated with hypertension such as fluid overload may have an additional effect on oxidative stress in PD patients.
EknoyanG.Cardiovascular mortality and morbidity in dialysis patients.Miner Electrolyte Metab1999 Jan–Apr; 25(1-2): 100–4.
2.
CollinsA.J., FoleyR.N., GilbertsonD.T., ChenS.C.The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis.Clin J Am Soc Nephrol2009 Dec; 4(Suppl 1): S5–11.
3.
HeerspinkH.J., NinomiyaT., ZoungasS., de ZeeuwD., GrobbeeD.E., JardineM.J.Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials.Lancet2009 Mar 21; 373(9668): 1009–15.
4.
VlachopoulosC., AznaouridisK., O'RourkeM.F., SafarM.E., BaouK., StefanadisC.Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis.Eur Heart J2010 Aug; 31(15): 1865–71.
5.
NicholsW.W., DenardoS.J., WilkinsonI.B., McEnieryC.M., CockcroftJ., O'RourkeM.F.Effects of arterial stiffness, pulse wave velocity, and wave reflections on the central aortic pressure waveform.J Clin Hypertens (Greenwich)2008 Apr; 10(4): 295–303.
6.
ChengH.M., LangD., TufanaruC., PearsonA.Measurement accuracy of non-invasively obtained central blood pressure by applanation tonometry: A systematic review and meta-analysis.Int J Cardiol2012; 167(5): [Epub ahead of print].
7.
WilliamsB., LacyP.S., YanP., HweeC.N., LiangC., TingC.M.Development and validation of a novel method to derive central aortic systolic pressure from the radial pressure waveform using an N-point moving average method.J Am Coll Cardiol2011 Feb 22; 57(8): 951–61.
8.
MontezanoA.C., TouyzR.M.Oxidative stress, Noxs, and hypertension: Experimental evidence and clinical controversies.Ann Med2012 Jun; 44(Suppl 1): S2–16.
9.
MontezanoA.C., TouyzR.M.Molecular mechanisms of hypertension—reactive oxygen species and antioxidants: a basic science update for the clinician.Can J Cardiol2012 May; 28(3): 288–95.
10.
VaziriN.D.Oxidative stress in uremia: nature, mechanisms, and potential consequences.Semin Nephrol2004 Sep; 24(5): 469–73.
11.
CarreroJ.J., StenvinkelP.Inflammation in end-stage renal disease—what have we learned in 10 years?Semin Dial2010 Sep–Oct; 23(5): 498–509.
12.
GuerinA., PannierB., LondonG.Atherosclerosis versus arterial stiffness in advanced renal failure.Adv Cardiol2007; 44: 187–98.
Witko-SarsatV., FriedlanderM., Capeillere-BlandinC., Nguyen-KhoaT., NguyenA.T., ZingraffJ.Advanced oxidation protein products as a novel marker of oxidative stress in uremia.Kidney Int1996 May; 49(5): 1304–13.
15.
KanedaH., TaguchiJ., OgasawaraK., AizawaT., OhnoM.Increased level of advanced oxidation protein products in patients with coronary artery disease.Atherosclerosis2002 May; 162(1): 221–5.
16.
PiwowarA., Knapik-KordeckaM., WarwasM.AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus.Diabetes Res Clin Pract2007 Aug; 77(2): 188–92.
17.
ValliA., SulimanM.E., MeertN., VanholderR., LindholmB., StenvinkelP.Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors.Clin Chim Acta2007 Apr; 379(1-2): 87–94.
18.
AnderstamB., Ann-ChristinB.H., ValliA., StenvinkelP., LindholmB., SulimanM.E.Modification of the oxidative stress biomarker AOPP assay: application in uremic samples.Clin Chim Acta2008 Jul 17; 393(2): 114–8.
19.
ResnickH.E., HarrisM.I., BrockD.B., HarrisT.B.American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey.Diabetes care2000 Feb; 23(2): 176–80.
20.
QureshiA.R., AlvestrandA., DanielssonA., Divino-FilhoJ.C., GutierrezA., LindholmB.Factors predicting malnutrition in hemodialysis patients: a cross-sectional study.Kidney Int1998 Mar; 53(3): 773–82.
21.
SectionI.Measurement of renal function, when to refer and when to start dialysis.Nephrol Dial Transplant2002; 17(Suppl 7): 7–15.
22.
NascimentoM.M., SulimanM.E., BruchfeldA., HayashiS.Y., ManfroR.C., QureshiA.R.The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients.Nephrol Dial Transplant2004 Dec; 19(12): 3112–6.
23.
BhatiaK., ElmarakbyA.A., El-RemessyA.B., SullivanJ.C.Oxidative stress contributes to sex differences in angiotensin II-mediated hypertension in spontaneously hypertensive rats.Am J Physiol Regul Integr Comp Physiol2012 Jan 15; 302(2): R274–82.
24.
HaqueM.Z., MajidD.S.High salt intake delayed angiotensin II-induced hypertension in mice with a genetic variant of NADPH oxidase.Am J Hypertens2011 Jan; 24(1): 114–8.
25.
WilcoxC.S.Effects of tempol and redox-cycling nitroxides in models of oxidative stress.Pharmacol Ther2010 May; 126(2): 119–45.
26.
KizhakekuttuT.J., WidlanskyM.E.Natural antioxidants and hypertension: promise and challenges.Cardiovasc Ther2010 Aug; 28(4): e20–32. PubMed PMID: 20370791.
27.
HarrisonD.G., GongoraM.C.Oxidative stress and hypertension.Med Clin North Am2009 May; 93(3): 621–35.
28.
ZalbaG., San JoseG., MorenoM.U., FortunoA., DiezJ.NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension.Antioxid Redox Signal2005 Sep–Oct; 7(9-10): 1327–36.
29.
RodrigoR., PratH., PassalacquaW., ArayaJ., BachlerJ.P.Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension.Clin Sci (Lond)2008 May; 114(10): 625–34.
30.
SchiffrinE.L.Antioxidants in hypertension and cardiovascular disease.Mol Interv2010 Dec; 10(6): 354–62.
31.
DemirciS., SekerogluM.R., NoyanT., KocerogluR., SoyoralY.U., DulgerH.The importance of oxidative stress in patients with chronic renal failure whose hypertension is treated with peritoneal dialysis.Cell Biochem Funct2011 Apr; 29(3): 249–54.
32.
KocakH., GumusluS., SahinE., CekenK., GocmenY.A., YakupogluG.Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients.Nephrology (Carlton)2009 Apr; 14(3): 273–80.
33.
MizunoY., JacobR.F., MasonR.P.Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.Am J Hypertens2008 Oct; 21(10): 1076–85.
34.
WeissW., GohlischC., Harsch-GladischC., TolleM., ZidekW., van der GietM.Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device.Blood Press Monit2012 Jun; 17(3): 128–31.
SelmeciL.Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome.Free Radic Res2011 Oct; 45(10): 1115–23.
ScollettaS., CarlucciF., BiagioliB., MarchettiL., MaccheriniM., CarlucciG.NT-proBNP changes, oxidative stress, and energy status of hypertrophic myocardium following ischemia/reperfusion injury.Biomed Pharmacother2007 Feb–Apr; 61(2-3): 160–6.
39.
CelikG., YontemM., CiloM., BilgeM., MehmetogluI., UnaldiM.The relationship between glutathione peroxidase and bioimpedance parameters in nondiabetic hemodialysis patients.Hemodial Int2012 Apr; 16(2): 274–81.
